분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2017-12-20 13:04:01 , Hit : 368
 Spark Therapeutics shares rise on FDA approval of new gene therapy for blindness

https://www.marketwatch.com/story/spark-therapeutics-shares-rise-on-fda-approval-of-new-gene-therapy-for-blindness-2017-12-19-1191742

Published: Dec 19, 2017 11:07 a.m. ET  

By Emma Court
Reporter

Spark Therapeutics Inc. ONCE, -0.22% shares rose 3% in heavy morning trade Tuesday after the company's gene therapy Luxturna was approved by the Food and Drug Administration for a rare type of inherited vision loss. Just one administration of the therapy could treat the disease, making it a major scientific breakthrough. The approval had been widely expected after an FDA committee recommended it in October, and was heralded by FDA Commissioner Scott Gottlieb as "another first in the field of gene therapy." The next, major question for the therapy is price, with some analysts projecting the cost could come close to $1 million. Gene therapies, the first of which was approved this past summer, are expected to challenge existing U.S. payment structures with their price tags, which are extremely high and cover a one-time treatment. Luxturna was approved for individuals with confirmed biallelic RPE65 mutation-associated retinal dystrophy, which is part of a group of eye disorders caused by gene mutations, can cause complete blindness in some cases and affects about 1,000 to 2,000 people in the U.S. Spark shares have plummeted 41.5% over the last three months, compared with a 7.2% rise in the S&P 500 SPX, -0.32% and a 10.8% rise in the Dow Jones Industrial Average DJIA, -0.15%







1227   암 면역요법, 일부 환자에게만 효과 있는 이유  이성욱 2018/01/12 587
1226   [바이오토픽] CRISPR 기반 유전자치료를 방해하는 면역계  이성욱 2018/01/10 589
1225   [미국] 2017년, 유전자가위 기술을 통한 네 가지 사건들  이성욱 2018/01/10 531
1224   Using Oncolytic Viruses to Boost Response to Immune Checkpoint Inhibitors  이성욱 2018/01/05 836
1223   Alcohol Boosts Cancer Risk by Damaging Stem Cell DNA  이성욱 2018/01/05 508
1222   [바이오토픽] Science, 2017년 과학연구 총결산  이성욱 2017/12/27 1006
1221   FDA Approves First Gene Therapy for Inherited Disease  이성욱 2017/12/22 510
  Spark Therapeutics shares rise on FDA approval of new gene therapy for blindness  이성욱 2017/12/20 368
1219   작년 바이오산업 규모 8조8775억원, 투자 13.9% 늘어  이성욱 2017/12/13 489
1218   CRISPR/Cas9 Edits Epigenome with Therapeutic Efficiency  이성욱 2017/12/09 484
1217   [바이오토픽] 체크포인트 저해제의 부작용: 자가면역질환 초래  이성욱 2017/11/16 686
1216   DNA Repair Mechanism Aids Cancer by Mending Chemo Damage  이성욱 2017/11/10 566
1215   FDA Approves Gilead CAR-T Therapy Yescarta, Plans Regenerative Medicine Policy 'Soon'  이성욱 2017/10/20 607
1214   Advisors to FDA Recommend Approval of Gene Therapy for Blindness  이성욱 2017/10/14 663
1213   CRISPR System Targets RNA in Mammalian Cells  이성욱 2017/10/06 639
1212   Nonviral CRISPR Delivery a Success  이성욱 2017/10/03 555
1211   Giants of Circadian Biology Win Nobel Prize  이성욱 2017/10/03 498
1210   To Speed CRISPR/Cas9’s Search and Snip, Try Extra Cas9 and gRNA  이성욱 2017/09/30 1988
1209   Technique Adapted from CRISPR-Cas9 Corrects Mutation in Human Embryos  이성욱 2017/09/29 502
1208   Mutations Making CRISPR Hyper-Accurate Discovered  이성욱 2017/09/22 851

[1][2] 3 [4][5][6][7][8][9][10]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN